TAO Synergies Inc. has made a significant move by registering a new securities offering, as outlined in its recent filing. This action is crucial for the company as it seeks to enhance its capital-raising capabilities and strengthen its position in the finance services sector.

Founded in Delaware, TAO Synergies Inc. operates under the SIC classification of 6199, which pertains to finance services. The company is listed on the Nasdaq under the ticker symbol TAOX. Its recent filings include an EFFECT form submitted on October 30, 2026, with an accession number of 9999999995-26-003382.

The filing states, "final effectiveness date is October 30, 2026," indicating that the registration of the new securities is now effective. This registration allows TAO Synergies to potentially attract new investments and expand its financial resources.

The new offering may affect various stakeholders, including investors looking for opportunities in the finance services industry. By enhancing its capital structure, TAO Synergies could also influence competitors in the finance sector, prompting them to explore similar avenues for growth and funding.

The filing does not say what happens next, but the effectiveness of this registration could lead to further developments in TAO Synergies' business strategy and market activities.

Company Background and Recent Changes

TAO Synergies Inc. was formerly known as Synaptogenix, Inc., having undergone a name change on December 10, 2020. Prior to that, the company was known as Neurotrope Bioscience, Inc., with the name change occurring on March 12, 2013. This evolution in the company's identity reflects its strategic shifts in focus and operations over the years.

The company is incorporated in Delaware and has a fiscal year-end of December 31. Its business address is located at 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036, and it can be contacted at the business phone number 973-242-0005.

Regulatory Details

The recent filing is categorized under the Securities Act of 1933, specifically as an S-3 form, which is typically used for securities offerings by companies that meet certain requirements. The SEC file number associated with this filing is 333-289612, indicating that it is part of a larger regulatory framework.

The filing indicates that the final effectiveness date is October 30, 2026, and was accepted on October 30, 2026, at 17:00:00.

While the filing details the effectiveness of the registration, it does not provide specific information about the terms of the securities being offered or the intended use of the proceeds from this offering.